List of Excipients in Branded Drug DEXMEDETOMIDINE

« Back to Dashboard

Generic Drugs Containing DEXMEDETOMIDINE

Company	Ingredient	NDC	Excipient
Accord Healthcare Inc	dexmedetomidine	16729-239	SODIUM CHLORIDE
Accord Healthcare Inc	dexmedetomidine	16729-239	WATER
Accord Healthcare Inc	dexmedetomidine	16729-432	SODIUM CHLORIDE
Accord Healthcare Inc	dexmedetomidine	16729-432	WATER

What are the Most Frequently-Used Excipients in DEXMEDETOMIDINE?

# Of NDCs	Excipient
16	SODIUM CHLORIDE
16	WATER

Dexmedetomidine Excipient Strategy and Commercial Opportunities

Last updated: October 10, 2026

Dexmedetomidine is a genericized injectable sedative with differentiated commercial opportunities in ready-to-use parenteral products, sublingual films, intranasal delivery, pediatric formulations, and device-enabled dosing. The active pharmaceutical ingredient is no longer the primary protection point. Value is concentrated in excipient selection, administration route, stability, packaging, dosing convenience, and regulatory positioning.

The strongest formulation opportunities are:

• Preservative-free, ready-to-use intravenous products
• Low-volume and high-concentration presentations
• Sublingual and buccal films
• Intranasal products for procedural and pediatric sedation
• Long-term stability in polymeric syringes and infusion systems
• Premixes that reduce pharmacy compounding
• Formulations that reduce hypotension, bradycardia, or administration errors

What is dexmedetomidine and how is it marketed?

Dexmedetomidine hydrochloride is a selective alpha-2 adrenergic receptor agonist used for sedation in intensive care, procedural settings, and acute agitation associated with schizophrenia or bipolar disorder. The reference injectable product is Precedex. Igalmi is a sublingual film approved in the United States for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. [1,2]

Product	Active ingredient	Route	Principal use	Commercial status
Precedex	Dexmedetomidine hydrochloride	Intravenous infusion	ICU and procedural sedation	Reference product; generic competition
Generic dexmedetomidine injection	Dexmedetomidine hydrochloride	Intravenous infusion	ICU and procedural sedation	Multiple ANDA-based products
Dexdor	Dexmedetomidine hydrochloride	Intravenous infusion	ICU sedation in jurisdictions outside the United States	Regional product
Igalmi	Dexmedetomidine hydrochloride	Sublingual film	Acute agitation in adults with schizophrenia or bipolar disorder	FDA-approved branded product

Dexmedetomidine is supplied as a salt because the hydrochloride form provides practical aqueous solubility and manufacturing consistency. The commercial challenge is less about discovering a new active ingredient than controlling pH, concentration, packaging compatibility, dose delivery, and product handling.

What excipients are used in dexmedetomidine products?

The excipient system depends on whether the product is an intravenous solution or a transmucosal film.

Intravenous injection excipients

Precedex and generic dexmedetomidine injections are generally aqueous, sterile, and intended for dilution or infusion. Product labels identify sodium chloride and water for injection in applicable presentations. Some products are supplied as concentrated solutions, while others are premixed in sodium chloride. [1,3]

The injectable excipient strategy is deliberately narrow:

Formulation objective	Relevant excipient or material	Commercial purpose
Isotonicity	Sodium chloride	Reduces hemolysis and infusion discomfort
Vehicle	Water for injection	Supports sterile aqueous delivery
pH control	Hydrochloric acid or sodium hydroxide, where applicable	Maintains formulation pH
Container compatibility	Glass, cyclic olefin polymer, polypropylene, or other validated materials	Limits adsorption and extractables
Infusion readiness	Sodium chloride premix	Reduces pharmacy preparation and dosing errors

A narrow excipient profile can simplify regulatory review and reduce tolerability concerns. It also limits formulation latitude. The main development burden shifts to stability, sterilization, container closure, dilution compatibility, and in-use shelf life.

Sublingual film excipients

Igalmi uses a polymeric sublingual film rather than an injectable solution. The FDA label identifies film-forming and functional excipients including hypromellose, pullulan, glycerin, maltodextrin, polysorbate 80, sucralose, and other formulation components disclosed in the product labeling. [2]

The film requires excipients that can:

• Form a uniform thin strip
• Dissolve rapidly under the tongue
• Maintain dose uniformity at low drug load
• Provide mechanical strength during packaging and handling
• Control moisture uptake
• Mask bitterness
• Avoid excessive salivation or premature swallowing
• Support rapid transmucosal absorption

The sublingual film creates a higher-value formulation platform than a conventional tablet because the dosage form combines polymer science, taste masking, packaging, and administration technique.

How should an excipient strategy be designed for dexmedetomidine injection?

The primary injectable formulation targets are chemical stability, physical stability, sterility, infusion compatibility, and operational simplicity.

pH and chemical stability

Dexmedetomidine hydrochloride is formulated in an acidic aqueous environment. pH must be controlled tightly because changes can affect degradation, solubility, color, preservative performance if preservatives are used, and compatibility with infusion fluids.

A commercial development program should evaluate:

1. API concentration and pH interaction
2. Degradation under accelerated and long-term conditions
3. Light sensitivity
4. Oxygen sensitivity
5. Compatibility with common diluents
6. Adsorption to infusion bags, tubing, and syringes
7. Stability after dilution
8. Stability during refrigerated and room-temperature handling

A low-excipient formula does not eliminate technical risk. It increases the importance of container closure, extractables and leachables, sterilization, and transportation studies.

Preservative-free positioning

Preservative-free dexmedetomidine is commercially attractive for intensive care, pediatrics, neonatology, and procedural sedation. A preservative-free product can support single-use packaging and reduce concerns about repeated-dose contamination.

The tradeoff is manufacturing complexity. Multi-dose formats require a validated preservative system and demonstrated antimicrobial effectiveness. A single-dose, preservative-free format avoids that requirement but can increase packaging and logistics costs.

Ready-to-use and premixed presentations

Ready-to-use products are the clearest near-term commercial opportunity in injectable dexmedetomidine. Hospitals have incentives to reduce:

• Pharmacy compounding
• Calculation errors
• Wrong-concentration administration
• Contamination risk
• Nursing preparation time
• Medication waste

A premixed bag or syringe can command a commercial premium over a concentrated vial even when the active ingredient is fully genericized. The product must demonstrate adequate stability in the selected container, including compatibility with infusion pumps and tubing.

High-concentration and low-volume products

A high-concentration formulation can reduce fluid burden in patients subject to fluid restriction. It may also support syringe-pump administration and transport in procedural settings.

The principal risks are dosing errors and accidental administration of an undiluted product. Commercial packaging should therefore use differentiated labeling, concentration-specific barcodes, connector controls, and clear dilution instructions.

What formulation patents can protect dexmedetomidine products?

Formulation patents can protect the product even when basic composition-of-matter protection has expired. The most defensible claims generally concern a defined combination of composition, performance, and use.

Potential claim categories include:

Patent category	Example protection
Aqueous injectable composition	Defined dexmedetomidine concentration, pH range, osmolality, and degradation limits
Ready-to-use formulation	Stable premix in a specified container for a defined shelf life
Container closure	Syringe, bag, vial, or polymer material that reduces adsorption or leachables
Sublingual film	Polymer matrix, plasticizer, surfactant, sweetener, and dissolution profile
Intranasal formulation	Mucoadhesive system, spray device, droplet size, and absorption performance
Manufacturing process	Mixing order, drying conditions, sterilization, or film-casting parameters
Method of use	Administration of a specified formulation for a defined patient population or clinical setting
Device combination	Dose-metered delivery system with a dexmedetomidine formulation

Broad claims covering dexmedetomidine alone are vulnerable because the active ingredient and basic therapeutic uses are established. Narrow claims tied to measurable product characteristics are more likely to have commercial value.

For a sublingual film, useful claim limitations may include:

• Film thickness
• Drug loading
• Content uniformity
• Mucoadhesion
• Dissolution time
• Residual moisture
• Tensile strength
• Packaging moisture barrier
• Sublingual exposure compared with swallowed administration

For an injectable product, the strongest claim strategy is usually a package of composition, container, and stability claims rather than a single broad formulation claim.

When does dexmedetomidine lose exclusivity?

The original injectable market has already moved into generic competition. Precedex's core active-ingredient exclusivity is no longer the main barrier to entry. Current commercial protection depends on product-specific patents, regulatory exclusivity, manufacturing capability, and customer contracts.

Exclusivity component	Injectable dexmedetomidine	Igalmi sublingual film
Active ingredient	Expired or commercially overcome	Not a practical barrier by itself
FDA approval pathway	ANDA for therapeutically equivalent injection	NDA pathway for branded film
Orange Book relevance	Product-specific listed patents, if any	Relevant to listed product patents
Generic entry mechanism	ANDA, including possible Paragraph IV certification	ANDA or other applicable abbreviated pathway if equivalence can be demonstrated
Biosimilar risk	None	None
Main commercial barrier	Sterile manufacturing and hospital supply	Film technology, clinical differentiation, patents, and market adoption

Dexmedetomidine is a small-molecule drug, not a biologic. Biosimilar competition is therefore not applicable. Competition occurs through generic drug applications, reformulated products, branded generics, and new delivery systems.

What is the Orange Book status of dexmedetomidine products?

The FDA Orange Book records approved drug products and, where applicable, patent and exclusivity information. Injectable generic dexmedetomidine products compete through ANDA approval and therapeutic equivalence rather than biosimilar pathways. Igalmi is regulated as an NDA product because the sublingual film and its clinical use represent a distinct dosage form and development program. [4]

Orange Book analysis should distinguish:

• The reference listed drug
• Approved strengths and dosage forms
• Therapeutic-equivalence codes
• Listed patents
• Regulatory exclusivity
• Patent certifications submitted by ANDA applicants
• Any 30-month stay associated with a Paragraph IV certification

A Paragraph IV challenge would be commercially meaningful only if an ANDA applicant can establish pharmaceutical equivalence and bioequivalence, or otherwise satisfy the applicable abbreviated pathway, while contesting listed patents. For a complex sublingual film, demonstrating equivalence may be more difficult than for a conventional injectable solution.

Which companies are competing in dexmedetomidine?

The competitive landscape has two layers: commodity injectable supply and differentiated delivery.

Injectable competition

The injectable market includes the reference product and multiple generic suppliers. Competition is based on:

• Shortage resilience
• Hospital group purchasing contracts
• Product availability
• Concentration and vial configuration
• Ready-to-use packaging
• Manufacturing capacity
• Backorder performance
• Pricing

Sterile injectable manufacturing is a meaningful barrier. A company may obtain regulatory approval but still fail commercially if it cannot maintain supply, qualify multiple component suppliers, or support hospital tenders.

Sublingual film competition

Igalmi is differentiated from injectable dexmedetomidine by avoiding intravenous access and enabling administration in a psychiatric or acute-care setting. Its commercial opportunity depends on adoption by emergency departments, psychiatric facilities, inpatient units, and managed-care systems.

The main competitive alternatives include:

• Intramuscular antipsychotics
• Oral antipsychotics
• Oral benzodiazepines
• Injectable dexmedetomidine in monitored settings
• Other agents used for acute agitation

The film's value proposition is strongest where rapid, non-injectable administration is clinically useful and swallowing is unreliable or undesirable.

What commercial opportunities exist for new dexmedetomidine formulations?

Ready-to-use hospital products

The most practical opportunity is a pre-diluted syringe or infusion bag with a validated shelf life. Hospital buyers may accept a premium for reduced preparation and lower medication-error risk.

Pediatric and neonatal formulations

Pediatric use creates demand for low-volume dosing, preservative-free packaging, and precise administration. A product designed around syringe pumps and weight-based dosing could differentiate from adult-oriented presentations. Pediatric development requires careful clinical and regulatory positioning because formulation convenience does not substitute for population-specific evidence.

Intranasal delivery

Intranasal dexmedetomidine could target procedural sedation, premedication, emergency care, and pediatric use. The formulation must manage nasal residence time, dose uniformity, spray performance, mucosal tolerability, and variable absorption.

Mucoadhesive polymers may improve residence time but can delay onset or produce unpleasant texture. Surfactants may improve wetting and absorption but increase irritation risk. The commercial objective is not maximum adhesion. It is reproducible exposure with acceptable tolerability.

Buccal and sublingual films

The film platform can support new strengths, dose bands, and packaging configurations. Commercial differentiation may come from:

• Faster dissolution
• Better taste masking
• Lower residual film mass
• Improved moisture protection
• Easier administration to agitated patients
• Unit-dose packaging
• Lower storage burden

A new film must show a meaningful advantage over the existing product or address a different clinical population. Minor excipient changes without improved performance are unlikely to create durable value.

Long-acting delivery

Long-acting injectable or implantable dexmedetomidine could reduce repeated administration, but the pharmacology creates a narrow safety margin. Prolonged exposure may increase the risk of hypotension, bradycardia, and delayed recovery. This opportunity has high technical and clinical risk compared with ready-to-use or transmucosal products.

How strong is the dexmedetomidine formulation patent estate?

The formulation patent estate is strongest for technically differentiated dosage forms and weakest for routine injectable compositions.

Opportunity	Patent strength	Development risk	Commercial attractiveness
Basic aqueous injection	Low to moderate	Low	Moderate
Ready-to-use premix	Moderate	Moderate	High
High-concentration injection	Moderate	Moderate	Moderate
Sublingual film	Moderate to high	High	High
Intranasal spray	Moderate	High	High
Long-acting depot	Potentially high	Very high	Uncertain
Packaging and device combination	Moderate	Moderate	Moderate

Patent strength improves when claims require a specific excipient system and produce a measurable technical result. Examples include a defined dissolution time, a narrow impurity profile, extended stability, reduced adsorption, or a validated pharmacokinetic profile.

Patent applicants should avoid relying exclusively on formulation composition claims. Process, packaging, device, and method-of-use claims can create overlapping protection and make design-around more difficult.

What litigation and settlement risks affect dexmedetomidine?

Injectable dexmedetomidine has a mature generic market, so the principal legal risks are ordinary ANDA litigation, product liability, manufacturing disputes, supply agreements, and shortages rather than biosimilar litigation.

For a branded sublingual film, the potential disputes include:

• Paragraph IV patent challenges
• Patent-infringement actions involving film composition or manufacturing
• Ownership disputes over film technology
• Licensing disputes
• Trade-secret claims involving casting or drying processes
• ANDA approval timing
• Settlement agreements affecting generic launch dates

Settlement analysis should focus on the agreed launch date, licensed rights, authorized-generic provisions, supply obligations, and restrictions on alternative dosage forms. A settlement can preserve commercial value while allowing earlier competition than full patent-term enforcement.

How does dexmedetomidine compare with competing sedatives?

Attribute	Dexmedetomidine	Midazolam	Lorazepam	Antipsychotic injection
Primary route	IV; sublingual film available	IV, IM, oral	IV, IM, oral	Usually IM
Respiratory depression	Generally lower than benzodiazepines, but clinically important risks remain	Higher risk	Higher risk	Variable
Hemodynamic effects	Bradycardia and hypotension are key risks	Less characteristic	Less characteristic	Variable
Non-injectable differentiated product	Sublingual film	Conventional oral forms	Conventional oral forms	Oral and IM
Formulation opportunity	Film, intranasal, premix	Multiple established forms	Multiple established forms	Long-established
Generic competition	High for injection	High	High	High

Dexmedetomidine's commercial advantage is route and setting flexibility. Its disadvantage is the need for monitoring in many clinical uses and the risk of bradycardia and hypotension.

What regulatory strategy supports a new dexmedetomidine product?

A conventional injectable can generally pursue an ANDA if it meets the requirements for pharmaceutical equivalence, bioequivalence, quality, and therapeutic equivalence. A materially different route, dosage form, strength, or clinical use may require an NDA or supplemental NDA pathway.

The regulatory strategy should align with the product's intended protection:

• Use an ANDA for a conventional equivalent injection.
• Use an NDA pathway for a new route or dosage form with clinical differentiation.
• Generate comparative stability and compatibility data for ready-to-use products.
• Generate human pharmacokinetic and clinical data for transmucosal products.
• Establish device performance for nasal sprays and dose-delivery systems.
• Link formulation claims to validated quality attributes.

Key Takeaways

• Dexmedetomidine's basic injectable market is genericized, shifting value from the API to formulation execution and supply reliability.
• The most commercially credible opportunities are ready-to-use injections, preservative-free pediatric products, sublingual films, and intranasal delivery.
• Sodium chloride and water for injection support the simple injectable platform; polymer, plasticizer, surfactant, sweetener, and moisture-barrier systems support the film platform.
• Formulation patents are strongest when they claim measurable performance, stability, packaging, or device attributes.
• Dexmedetomidine has no biosimilar risk because it is a small molecule.
• Orange Book and Paragraph IV analysis is most relevant to branded dosage forms such as Igalmi and to any later product with listed patents.
• Sterile manufacturing capacity and hospital purchasing access can be as important commercially as patent term.
• A ready-to-use product can command value even when the active ingredient is available from multiple generic suppliers.

FAQs

Can dexmedetomidine be formulated without sodium chloride?

Yes. Sodium chloride is used in applicable injectable presentations for isotonicity, but alternative tonicity systems can be evaluated if they preserve stability, tolerability, and infusion compatibility.

Which excipients are most important for dexmedetomidine sublingual films?

The key categories are film-forming polymers, plasticizers, moisture-control agents, surfactants, sweeteners, and taste-masking components. Performance depends on the combined system rather than one excipient.

Is intranasal dexmedetomidine commercially viable?

Yes, particularly for pediatric premedication, procedural sedation, and settings where intravenous access is undesirable. The principal development risks are dose uniformity, variable absorption, nasal tolerability, and device performance.

Can a generic company patent a dexmedetomidine formulation?

Yes. A generic company can seek patents covering a distinct composition, manufacturing process, container, device, stability profile, or method of use, provided the claims satisfy novelty, non-obviousness, written-description, and enablement requirements.

What is the highest-value dexmedetomidine product opportunity?

A differentiated, ready-to-use or transmucosal product with clear workflow advantages is more attractive than another conventional concentrated vial. The strongest opportunity depends on regulatory feasibility, hospital adoption, manufacturing reliability, and the ability to obtain enforceable formulation or device claims.

References

1. U.S. Food and Drug Administration. (2023). Precedex (dexmedetomidine hydrochloride) injection prescribing information.
2. U.S. Food and Drug Administration. (2022). Igalmi (dexmedetomidine) sublingual film prescribing information.
3. U.S. Food and Drug Administration. (2024). DailyMed: Dexmedetomidine hydrochloride injection labeling. National Library of Medicine.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.